These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31721578)

  • 21. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
    Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
    Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 23. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
    Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
    J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
    Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
    Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
    Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK
    Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KIT
    Banerjee S; Yoon H; Ting S; Tang CM; Yebra M; Wenzel AT; Yeerna H; Mesirov JP; Wechsler-Reya RJ; Tamayo P; Sicklick JK
    Mol Cancer Ther; 2021 Oct; 20(10):2035-2048. PubMed ID: 34376580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
    Hsueh YS; Lin CL; Chiang NJ; Yen CC; Li CF; Shan YS; Ko CH; Shih NY; Wang LM; Chen TS; Chen LT
    PLoS One; 2013; 8(6):e65762. PubMed ID: 23840364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
    Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
    Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.
    Yuan X; Chen Y; Zhang W; He J; Lei L; Tang M; Liu J; Li M; Dou C; Yang T; Yang L; Yang S; Wei Y; Peng A; Niu T; Xiang M; Ye H; Chen L
    J Med Chem; 2019 Apr; 62(8):4158-4173. PubMed ID: 30939008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
    Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
    Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors.
    Takaki EO; Kiyono K; Obuchi Y; Yamauchi T; Watanabe T; Matsumoto H; Karimine M; Kuniyoshi Y; Nishikori S; Yokoyama F; Nishimori H; Nabeshima H; Nakamura K
    Clin Cancer Res; 2024 Aug; 30(16):3603-3621. PubMed ID: 38864850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-
    Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J
    J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
    Saito Y; Takahashi T; Obata Y; Nishida T; Ohkubo S; Nakagawa F; Serada S; Fujimoto M; Ohkawara T; Nishigaki T; Sugase T; Koh M; Ishida T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Yamasaki M; Hirota S; Naka T; Mori M; Doki Y
    Br J Cancer; 2020 Mar; 122(5):658-667. PubMed ID: 31857719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
    García-Valverde A; Rosell J; Sayols S; Gómez-Peregrina D; Pilco-Janeta DF; Olivares-Rivas I; de Álava E; Maurel J; Rubió-Casadevall J; Esteve A; Gut M; Valverde C; Barretina J; Carles J; Demetri GD; Fletcher JA; Arribas J; Serrano C
    Oncogene; 2021 Dec; 40(48):6614-6626. PubMed ID: 34621020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.
    Gebreyohannes YK; Burton EA; Wozniak A; Matusow B; Habets G; Wellens J; Cornillie J; Lin J; Nespi M; Wu G; Zhang C; Bollag G; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Exp Med; 2019 May; 19(2):201-210. PubMed ID: 30523507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
    Hsueh YS; Chang HH; Shan YS; Sun HS; Fletcher JA; Li CF; Chen LT
    Oncogene; 2019 Sep; 38(38):6550-6565. PubMed ID: 31363162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants.
    Wu TS; Lin WH; Tsai HJ; Hsueh CC; Hsu T; Wang PC; Lin HY; Peng YH; Lu CT; Lee LC; Tu CH; Kung FC; Shiao HY; Yeh TK; Song JS; Chang JY; Su YC; Chen LT; Chen CT; Jiaang WT; Wu SY
    J Med Chem; 2019 Apr; 62(8):3940-3957. PubMed ID: 30968693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.